Literature DB >> 6407830

Post-transfusion hepatitis and its association with pooled clotting factors.

U Sugg, G G Frösner, R Lissner, R Stunkat, W Schneider.   

Abstract

A prospective study of post-transfusion hepatitis was conducted in 97 adult patients undergoing open heart surgery. Twelve patients developed presumed non-A, non-B hepatitis (five of these were hospitalized and three were jaundiced), and all 12 had received clotting factors from pooled plasma (fibrinogen, factor VIII, factor IX complex) from different manufacturers. Of the remaining 85 patients none received these high risk plasma derivatives and none developed hepatitis. Multiple peak ALT elevation seems to be an indication of development of chronic non-A, non-B hepatitis. In addition to the 12 cases of presumed non-A, non-B hepatitis, nine cases of serological changes related to hepatitis B virus were observed as follows: six early booster reactions of anti-HBs, but not anti-HBc, in anti-HBs and anti-HBc positive persons; one late immunization-like response for anti-HBs and two serological hepatitis B infections without transaminase elevation. Five of the nine cases were also associated with the administration of pooled clotting factors.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6407830     DOI: 10.1007/BF02001579

Source DB:  PubMed          Journal:  Eur J Clin Microbiol        ISSN: 0722-2211            Impact factor:   3.267


  22 in total

1.  Transfusion-related short-incubation hepatitis in hemophilic patients.

Authors:  M A Hruby; V Schauf
Journal:  JAMA       Date:  1978-09-22       Impact factor: 56.272

2.  Post-transfusion hepatitis in Italy.

Authors:  F Tremolada; G Realdi; F Noventa; A Alberti; E Pornada; C Valfre; V Gallucci
Journal:  Lancet       Date:  1982-04-10       Impact factor: 79.321

3.  Post-transfusion hepatitis in Australia. Report of the Australian Red Cross study.

Authors:  Y E Cossart; S Kirsch; S L Ismay
Journal:  Lancet       Date:  1982-01-23       Impact factor: 79.321

4.  beta-propiolactone/ultraviolet irradiation: a review of its effectiveness for inactivation of viruses in blood derivatives.

Authors:  A M Prince; W Stephan; B Brotman
Journal:  Rev Infect Dis       Date:  1983 Jan-Feb

5.  An outbreak of hepatitis associated with intravenous injection of factor-VIII concentrate.

Authors:  J Craske; N Dilling; D Stern
Journal:  Lancet       Date:  1975-08-02       Impact factor: 79.321

6.  Efficacy of prophylactic gamma-globulin in preventing non-A, non-B post-transfusion hepatitis.

Authors:  R G Knodell; M E Conrad; A L Ginsberg; C J Bell
Journal:  Lancet       Date:  1976-03-13       Impact factor: 79.321

7.  Type B hepatitis after transfusion with blood containing antibody to hepatitis B core antigen.

Authors:  J H Hoofnagle; L B Seeff; Z B Bales; H J Zimmerman
Journal:  N Engl J Med       Date:  1978-06-22       Impact factor: 91.245

8.  Immunoglobulin M antibodies to hepatitis B core antigen: evaluation of enzyme immunoassay for diagnosis of hepatitis B virus infection.

Authors:  M Roggendorf; F Deinhardt; G G Frösner; R Scheid; B Bayerl; R Zachoval
Journal:  J Clin Microbiol       Date:  1981-04       Impact factor: 5.948

9.  Transmission of non-A non-B hepatitis to chimpanzees by factor-IX concentrates after fatal complications in patients with chronic liver disease.

Authors:  R J Wyke; K N Tsiquaye; A Thornton; Y White; B Portmann; P K Das; A J Zuckerman; R Williams
Journal:  Lancet       Date:  1979-03-10       Impact factor: 79.321

10.  Viruslike particles in a plasma fraction (fibrinogen) and in the circulation of apparently healthy blood donors capable of inducing non-A/non-B hepatitis in humans and chimpanzees.

Authors:  H Yoshizawa; Y Akahane; Y Itoh; S Iwakiri; K Kitajima; M Morita; A Tanaka; T Nojiri; M Shimizu; Y Miyakawa; M Mayumi
Journal:  Gastroenterology       Date:  1980-09       Impact factor: 22.682

View more
  1 in total

1.  Prevalence of antibody to delta hepatitis virus in population groups in West Germany and Switzerland.

Authors:  G G Frösner; E Franco; J Altorfer; R H Decker; I K Mushahwar
Journal:  Eur J Clin Microbiol       Date:  1985-04       Impact factor: 3.267

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.